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The influence of smoking on endovascular
abdominal aortic aneurysm repair
Dave Koole, MD,a,b Frans L. Moll, MD, PhD,a Jacob Buth, MD, PhD,c Roel Hobo, PhD,c
Herman Zandvoort, MD,a Gerard Pasterkamp, MD, PhD,b and Joost A. van Herwaarden, MD, PhD,a
the EUROSTAR collaborators, Utrecht and Eindhoven, The Netherlands
Objective: The main purpose of this study was to evaluate the influence of smoking on perioperative outcomes of
endovascular aneurysm repair (EVAR), aneurysm sac behavior, abdominal aortic aneurysm (AAA) neck growth after
EVAR, and its effect on stent graft migration during follow-up.
Methods: Baseline characteristics and follow-up data were collected prospectively by patient record forms. Follow-up visits
were scheduled at 1, 3, 6, 12, 18, and 24months, and annually thereafter and included a clinical examination and imaging
studies. Patients were stratified in three groups according to their smoking status as nonsmokers, former smokers, and
smokers.
Results: This study analyzed the data for 4176 nonsmokers, 2406 former smokers, and 2056 smokers who were enrolled
prospectively in the European Collaborators on Stent-Graft Techniques for Aortic Aneurysm Repair (EUROSTAR)
database. Compared with nonsmokers, smokers required more percutaneous transluminal angioplasty and stent place-
ments during EVAR (P < .001), and stent graft migration occurred more often (hazard ratio, 1.45; 95% confidence
interval, 1.03-2.05; P  .033). Nonsmokers had more late type II endoleaks than former smokers and smokers (58.5%,
55.9%, and 35.5%, respectively; P < .001). Smoking had no effect on aneurysm sac behavior or AAA neck growth after
EVAR.
Conclusions: Smokers need more percutaneous transluminal angioplasty procedures and stents during EVAR. They have
fewer late type II endoleaks during follow-up; however, smokers should be closely monitored because they have an
increased risk of stent graft migration. (J Vasc Surg 2012;55:1581-6.)
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fSeveral studies have found a strong coexistence of
smoking and abdominal aortic aneurysm (AAA) disease.1-6
Smokers have an increased prevalence and expansion rate of
AAA disease,1-10 and smoking increases the risk of a rup-
tured AAA by twofold.11 Theories to explain the influence
of smoking on AAA disease include disruption in collagen
synthesis, altered expression of metalloproteinases, and an
increased level of oxidative stress.5,6 Furthermore, smoking
has prothrombotic effects.12 These biologic processes un-
der the influence of smoking might also have an effect on
endovascular aneurysm repair (EVAR). A European Col-
laborators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) study from 2004 analyzed the effect
of smoking on EVAR outcome for the first time in a large
cohort of 3270 (2417 nonsmokers and 853 smokers) indi-
viduals. Smokers required a higher number of percutane-
ous transluminal angioplasty (PTA) procedures and stents
but had a reduced risk of late type II endoleaks.13
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doi:10.1016/j.jvs.2011.12.018We performed an updated analysis of the EUROSTAR
atabase and investigated the influence of smoking on
VAR outcome, not only for smokers and nonsmokers but
lso for former smokers. In addition to the previous study,
e analyzed the effects of smoking on postoperative mor-
hologic aortic changes and on stent graft migration in a
ohort of 8638 patients (4176 nonsmokers, 2406 former
mokers, and 2056 smokers). The main purpose of this
tudy was to evaluate the influence of smoking on the
erioperative outcomes of EVAR, aneurysm sac behavior,
AA neck growth after EVAR, and on stent graft migration
uring follow-up.
ETHODS
Studypopulation andorganizationof theEUROSTAR
egistry. For a description of the EUROSTAR organiza-
ion, we refer to earlier published studies.14-17 Patient
haracteristics, operative details, and follow-up data were
ollected by patient record forms or by using an on-line
ormat (KIKA-Medical, Nancy, France). Follow-up visits,
ccording to the protocol, were scheduled at 1, 3, 6, 12, 18,
nd 24 months, and annually thereafter. During follow-up
isits, clinical and imaging data were gathered on data
orms and were returned at standard times to the Data
egistry Center for analysis. Data for 8638 patients who
ere enrolled prospectively in the EUROSTAR database
etween 1996 and 2006 constituted the basis for this
nalysis. Patients without a recorded smoking status and
ollow-up were excluded from the analysis. Smoking status
as registered according to the Society for Vascular Surgery
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(ISCVS) risk score system.
This analysis stratified patients in three groups: patients
who never smoked or had not smoked in the last 10 years
were classified as nonsmokers, former smokers consisted of
patients who did not smoke at the time of inclusion but
smoked in the last 10 years, and patients who actively
smoked at the time of inclusion were classified as smokers.
Early adverse outcome was defined as complications 30
days after surgery. Late adverse outcome was defined as
postoperative complications occurring 30 days.
Aneurysm growth was determined by the recording of
an increase in aneurysm diameter measured at its largest
section, from outer wall to outer wall across the minor
diameter, on axial computed tomography, ultrasound, or
magnetic resonance imaging. Aneurysm enlargement was
defined as a diameter increase of at least 8 mm relative to
the preoperative diameter measurements on the included
image assessment.18 The maximum recorded aneurysm
diameter during follow-up was used for this analysis. This
relatively high threshold of 8 mm in EUROSTAR is due to
the presumed larger interobserver variability in the registry.
Earlier EUROSTAR studies have chosen this threshold
considering growth.18-21 To account for relative AAA in-
frarenal neck changes during follow-up, an increase of
15% in transverse aortic neck diameter measured 3 mm
distally from the lowermost renal artery was considered
significant.
Statistical analysis. Results are expressed as mean
(standard deviation) or as frequencies (percentages). To
assess for differences in baseline characteristics or operative
complications among the defined study groups, we used 2
tests for discrete variables and analysis of variance tests for
continuous variables. Cumulative rates of freedom from an
adverse outcome after EVAR were assessed with Kaplan-
Meier analysis. Rates with 10% standard error are indi-
cated in the results. Significant differences between the
defined study groups were assessed with log-rank testing. A
multivariable logistic regression or Cox regression analysis
was used to assess independent associations. Smoking was
Table I. Characteristics of patients at baseline
Characteristicsa Nonsmokers (n 
Age, mean (SD), years 73.2 (7.3)
Male sex 3790 (90.8
ASA 2 1985 (48.3
Diabetes 481 (11.5
History of cardiac symptoms or interventions 2494 (59.7
Renal insufficiency 720 (17.2
Pulmonary symptoms 1322 (32.1
Hypertension 2589 (62.3
Obesity 1012 (24.5
Previous laparotomy 1121 (27.1
Drug-controlled hypercholesterolemia 561 (13.8
ASA, American Society of Anesthesiologists; SD, standard deviation.
aData are shown as frequency (percentage) unless stated otherwise. Missingadjusted by multivariable analysis for age, sex, diabetes, aypertension, drug-controlled hypercholesterolemia, renal
nsufficiency, pulmonary status, history of cardiac symp-
oms or interventions, obesity, American Society of Anes-
hesiologists score 2, coexisting common iliac aneurysm,
eck, and aneurysm size, AAA infrarenal neck length, arte-
ial angulations, type of stent graft, perfusion of the mes-
nteric inferior or lumbar arteries, and preoperative or
ntraoperative embolization of the mesenteric inferior or
umbar arteries. All tests were two-sided, with P  .05
onsidered statistically significant. Statistical analyses
ere performed with SPSS 15.0 software (SPSS Inc,
hicago, Ill).
ESULTS
Baseline characteristics. The study population be-
ween 1996 and 2006 consisted of 8638 EVAR patients
8063 men and 575 women) who were a mean age of 72
ears (range, 34-100 years); of these, 4176 were nonsmok-
rs, 2406 were former smokers, and 2056 were smokers.
atient characteristics of the study population are given in
able I. The mean aneurysm diameter was 58 mm (range,
6-172 mm). Former smokers and smokers had a higher
revalence of aneurysmal common iliac arteries (P .005).
etails of morphologic characteristics between the study
roups are reported in Table II.
The effect of smoking on early adverse outcome.
ompared with nonsmokers, former smokers and smokers
eeded more additional procedures at the time of surgery
P .001), which consisted mainly of an increased number
f PTA procedures or stents for stenosis (10.5%, 11.8%, and
3.7%, respectively; P  .040). No differences were ob-
erved among the study groups for iliofemoral or crossover
ypasses. Adjusted analysis showed more endoleaks at the
ime of surgery in nonsmokers compared with former
mokers and smokers (18.7%, 15.0%, and 14.1%, respec-
ively; P  .037). Perfusion from lumbar arteries or the
nferior mesenteric artery was significantly lower in active
nd former smokers compared with nonsmokers (7.6%,
.8%, and 11.0%, respectively; P .007). Additional oper-
) Former smokers (n  2406) Smokers (n  2056) P
70.9 (7.5) 68.9 (8.0) .001
2320 (96.4) 1953 (95.0) .001
1269 (53.1) 1031 (50.9) .001
302 (12.7) 266 (13.1) .157
1567 (65.1) 1110 (54.0) .001
549 (22.8) 353 (17.2) .001
1137 (48.0) 993 (49.0) .001
1667 (69.9) 1251 (61.3) .001
682 (28.4) 572 (27.9) .001
613 (25.5) 564 (27.5) .251
330 (14.0) 265 (13.3) .772
anged from 0 to 122 per variable.4176
)
)
)
)
)
)
)
)
)
)tive details are listed in Table III. No differences were
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Volume 55, Number 6 Koole et al 1583observed in postoperative complications, defined as AAA
rupture, conversion, or device-related complications.
Follow-up. Mean duration of follow-up was 26.0
months (range, 1-96 months). Mean follow-up was 25.4
months for nonsmokers, 26.2 months for former smokers,
and 27.0 months for smokers.
The effect of smoking on late adverse outcome. The
overall effect of smoking on late stent graft migration was
not significant (P  .099); however, significantly more
stent graft migrations occurred in smokers (hazard ratio,
1.45; 95% confidence interval, 1.03-2.05; P  .033) than
in nonsmokers. There was no significant difference in kink-
ing, stenosis, or stent graft thrombosis during follow-up
among the study groups. The occurrence of type II en-
doleaks at 8 years was 58.5% for nonsmokers, 55.9% for
former smokers, and 35.5% for smokers (P  .001); fur-
thermore, adjusted analysis demonstrated no significant
difference for proximal or distal type I and type III en-
doleaks. No significant differences in transfemoral reinter-
vention, conversion, rupture, or AAA death rate were ob-
served (Table IV).22
The effect of smoking on aneurysm morphology
after EVAR. Occurrence of AAA sac enlargement after
EVAR was not significantly different between the study
groups at 8 years: 51.0% for nonsmokers, 57.9% for former
smokers, and 41.7% for smokers (P  .144). AAA shrink-
age (8 mm) at 8 years was less frequent in nonsmokers
Table II. Morphologic abdominal aortic aneurysm (AAA
Morphologic characteristicsa Nonsmokers (n  4176)
AAA diameter, mean (SD), mm 57.8 (12.0)
Infrarenal aortic neck
Diameter, mean (SD), mm 23.6 (3.2)
Length, mean (SD), mm 28.3 (12.7)
Aneurysmal common iliac arteries 358 (8.6)
Angulation
Aortic neck 908 (27.1)
Aneurysm 484 (11.6)
Right iliac 1341 (32.1)
Left iliac 1514 (36.3)
SD, Standard deviation.
aCharacteristics are presented as frequency (percentage), unless otherwise in
Table III. Intraoperative details of the study population
Intraoperative details
Nonsmokers (n  4176) Former s
No. (%)
Additional procedures 1104 (26.4)
PTA/stent for stenosis 438 (10.5)
Endarterectomy 46 (1.1)
Iliofemoral bypass 25 (0.6)
Crossover bypass 217 (5.2)
Uncovered stent 129 (3.1)
Early endoleaks 782 (18.7)
Lumbar or IMA perfusion 461 (11.0)
IMA, Inferior mesenteric artery; PTA, percutaneous transluminal angioplasthan in smokers and former smokers (26.0%, 32.8% and a3.8%, respectively; P  .003). There was no significant
ifference at 8 years in infrarenal aortic neck diameter
ncrease among the nonsmokers, former smokers, and
mokers (P .148). A subanalysis to exclude the influence
f endoleaks showed there was no difference in postopera-
ive AAA shrinkage among the study groups. Further de-
ails are reported in Table V.
ISCUSSION
Smoking has detrimental effects on AAA prevalence,
rowth rate, and rupture risk.1-11 The biologic mechanisms
re largely unsolved. Theories include higher proteolysis,
xtracellular matrix disruptions, and increased levels of free
adicals. This study investigated the influence of smoking
n adverse outcomes among nonsmokers, former smokers,
nd smokers. The SVS-ISCVS risk score classifies non-
mokers as patients who never smoked, and patients who
ever smoked in the last 10 years. This time frame of 10
ears of nonsmoking nearly eliminates the excess risk for
eripheral arterial disease and puts the group in the non-
moking category.23-25 Former smokers consisted of pa-
ients who did not smoke at the time of inclusion but
moked in the last 10 years. This group has a reduced risk
or peripheral arterial disease compared with smokers but
as a higher risk for peripheral arterial disease than non-
mokers.23-25
The current study observed more additional intraoper-
racteristics of the study population
Former smokers (n  2406) Smokers (n  2056) P
57.5 (11.7) 56.8 (11.4) .008
23.7 (3.1) 23.7 (3.2) .282
27.2 (12.0) 27.5 (12.4) .003
260 (10.8) 215 (10.5) .005
539 (22.4) 448 (21.8) .810
246 (10.2) 219 (10.7) .200
756 (31.4) 640 (31.1) .697
879 (36.5) 745 (36.2) .970
d. Missing data ranged from 0 to 550 per variable.
rs (n  2406) Smokers (n  2056) P
(%) No. (%) Unadjusted Adjusted
31.1) 678 (33.0) .001 .001
11.8) 282 (13.7) .001 .040
2.0) 38 (1.8) .009 .083
0.8) 15 (0.7) .537
5.7) 121 (5.9) .472
3.4) 67 (3.3) .774
15.0) 289 (14.1) .001 .037
8.8) 156 (7.6) .001 .007) chamoke
No.
749 (
285 (
47 (
20 (
137 (
82 (
360 (
211 (tive procedures, which consisted mainly of PTA proce-
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June 20121584 Koole et aldures or stents, in smokers and former smokers than in
nonsmokers. There was also a higher frequency of endar-
terectomy in former smokers and smokers; however, this
did not reach statistical significance on multivariable anal-
ysis. Although there was a statistically significant difference
in PTA procedures or stents during surgery, this difference
was very small in absolute numbers.
The study observed decreased intraoperative perfusion
Table IV. Late complications of the study population
Late complications
Nonsmokers
(n  4176)
Former
smokers
(n  2406)
Smokers
(n  2056)
No. (%)c No. (%)c No. (%)c Fo
Stent graft migration 102 (2.4) 69 (2.9) 83 (4.0) 1.1
Stent kinking 115 (2.8) 63 (2.6) 67 (3.3) 0.9
Stenosis or stent
thrombosis 156 (3.7) 93 (3.9) 92 (4.5) 1.0
Endoleakd
Type I
Proximal 166 (4.0) 65 (2.7) 60 (2.9) 0.6
Distal 201 (4.8) 96 (4.0) 77 (3.7) 0.8
Type II 680 (16.3) 299 (12.4) 188 (9.1) 0.7
Type III 226 (5.4) 96 (4.0) 78 (3.8) 0.7
Transfemoral
reinterventions 334 (8.0) 172 (7.1) 155 (7.5) 0.8
Conversion 100 (2.4) 61 (2.5) 62 (3.0) 1.0
Rupture 36 (0.9) 23 (1.0) 20 (1.0) 1.0
AAA death 75 (1.8) 50 (2.1) 38 (1.8) 1.1
AAA, Abdominal aortic aneurysm; CI, confidence interval.
aUnadjusted hazard ratio (95% CI) for late complications was calculated by
bAdjusted hazard ratio (95% CI) for late complications was calculated by m
cRepresents absolute patient numbers and percentages and does not include
dEndoleaks have been categorized according to the May-White classificatio
Table V. Morphologic abdominal aortic aneurysm (AAA)
AAA changes
Nonsmokers
(n  4176)
Former
smokers
(n  2406)
Smokers
(n  2056)
No. (%)c No. (%)c No. (%)c Fo
Enlargement 8 mm 320 (7.7) 156 (6.5) 139 (6.8) 0.8
Shrinkage 8 mm 326 (7.8) 199 (8.3) 208 (10.1) 1.0
Neck growth 15% 751 (18.0) 411 (17.1) 377 (18.3) 0.8
(n  2786) (n  1756) (n  1531)
Without endoleaks
(subanalysis)
Enlargement 8 mm 141 (5.1) 94 (5.4) 81 (5.3) 1.0
Shrinkage 8 mm 291 (10.4) 182 (10.4) 187 (12.2) 0.9
Neck growth 15% 528 (19.0) 326 (18.6) 316 (20.6) 0.8
CI, Confidence interval.
aUnadjusted hazard ratio and 95% CI for late complications was calculated
bAdjusted HR with 95% CI for late complications was calculated by multiva
cRepresents absolute patient numbers and percentages, and does not includfrom the mesenteric inferior artery or lumbar arteries in mmokers. Atherosclerosis might narrow or occlude these
rteries and thereby impair the blood flow. There is also an
ncreased tendency of coagulation in smokers, which also
ight narrow or occlude the arteries.12 These factors could
xplain why smokers have a lower risk of early endoleaks
nd late type II endoleaks.
Stent graft migration was significantly increased in
mokers. Nonsmokers and former smokers had the same
Hazard ratio (95% CI)
Unadjusteda Adjustedb
smoker Smoker Former smoker Smoker
83-1.53) 1.50 (1.12-2.01) 1.23 (0.87-1.72) 1.45 (1.03-2.05)
67-1.25) 1.07 (0.79-1.45)
78-1.30) 1.12 (0.87-1.45)
50-0.88) 0.69 (0.52-0.93) 0.67 (0.49-0.93) 0.81 (0.58-1.13)
63-1.02) 0.72 (0.55-0.94) 0.77 (0.59-1.01) 0.74 (0.54-1.01)
65-0.85) 0.53 (0.45-0.63) 0.83 (0.71-0.96) 0.64 (0.53-0.76)
56-0.90) 0.66 (0.51-0.85) 0.82 (0.63-1.06) 0.82 (0.61-1.10)
72-1.04) 0.87 (0.72-1.06)
75-1.41) 1.18 (0.86-1.63)
64-1.81) 1.06 (0.61-1.82)
79-1.62) 0.99 (0.67-1.47)
riable Cox regression analysis with nonsmokers as reference category.
iable Cox regression analysis with nonsmokers as reference category.
nts censored or lost to follow-up in the years after surgery.
toperative changes of the study population
Hazard ratio (95% CI)
Unadjusteda Adjustedb
smoker Smoker Former smoker Smoker
7-0.98) 0.81 (0.66-0.98) 0.81 (0.66-1.00) 0.93 (0.74-1.17)
5-1.22) 1.22 (1.08-1.45) 1.08 (0.88-1.31) 1.39 (1.14-1.69)
7-0.98) 0.97 (0.85-1.09) 0.95 (0.84-1.08) 1.10 (0.96-1.26)
.77-1.30) 0.95 (0.72-1.25)
.79-1.14) 1.09 (0.91-1.31)
.78-1.02) 1.02 (0.88-1.17)
variable Cox regression analysis with nonsmokers as reference category.
Cox regression analysis with nonsmokers as reference category.
ents censored or lost to follow-up in the years after surgery.rmer
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because of the increased stiffness of a more atherosclerotic
abdominal aorta in smokers. A rigid aorta can decrease
fixation of the stent graft; however, this does not explain
why former smokers and nonsmokers have similar stent
graft migration rates. Smokers and former smokers in this
study cohort had more aneurysmal common iliac arteries
and shorter AAA neck lengths. These factors might increase
the risk for stent graft migration but were included in the
multivariable analysis; therefore, it seems unlikely that these
factors solely explain the increased risk of stent graft migra-
tion in smokers.
Another possible theory is that smokers have more
stent graft migration due to increased AAA neck calcifica-
tion and thrombus.Modern stent grafts have better fixation
properties. Therefore, it would be interesting to investigate
stent graft migration rates in smokers vs nonsmokers in a
database with stent grafts in current use to see whether
these factors have an influence on stent graft migration
rates.
Because smokers have faster AAA growth rates than
nonsmokers in the preoperative AAA phase26 and we ob-
served more stent graft migration in smokers postopera-
tively, we also analyzed the effects of smoking on AAA
growth after EVAR. Rates of sac enlargement or aneurysm
neck growth did not differ among the study groups; how-
ever, we observed more sac shrinkage in smokers compared
with former smokers and nonsmokers. Smokers have fewer
late type II endoleaks, and this could be a possible con-
founding factor and cause a type I error. We therefore
performed a subanalysis of smoking on AAA growth with-
out endoleaks. In the subanalysis, no effect of smoking on
AAA enlargement, AAA shrinkage, or more than 15% an-
eurysm neck diameter increase was observed. Furthermore,
Timaran et al27 observed no significant influence of smok-
ing on AAA enlargement in patients with persistent type II
endoleaks. Biologic processes initiated by smoking do not
seem to have a strong influence on AAA sac behavior or
AAA neck growth after EVAR treatment. This is in contrast
with the situation before EVAR treatment, where smoking
seems to be one of the strongest risk factors for AAA
development, progression, and rupture.
Several limitations need to be addressed. Because we
were not able to measure circulating cotinine concentra-
tions, and previous studies revealed that patients might
under-report their smoking habits,28 this might have cre-
ated a bias. If there are nonsmokers in the database who are
actually smokers, then this might weaken the differences
between nonsmokers, former smokers, and smokers con-
cerning the results. Some patients might also quit smoking
after surgery, or vice versa, which could bias the postoper-
ative results. Furthermore, the database did not document
the years of smoking cessation, which prevented us from
analyzing the question of how many years of smoking
cessation are necessary to derive a benefit from smoking
cessation.
Another limitation is the large number of patients who
were lost to follow-up, which was 67.7% for nonsmokers,6.0% for former smokers, and 65.0% for smokers after 2
ears. Despite this limitation, a standard error of 10%
fter 8 years in the survival analysis is statistically adequate
or a valid assessment.
ONCLUSIONS
This EUROSTAR update confirms that smokers and
ormer smokers need more PTA procedures and stent
lacement during EVAR. Smokers and former smokers
ave fewer early endoleaks, probably due to decreased
erfusion of the inferior mesenteric artery or lumbar arter-
es, and also fewer late type II endoleaks during follow-up.
owever, they should be closely monitored because smok-
rs have an increased risk of stent graft migration.
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